Biora Therapeutics, Inc. (NASDAQ:BIOR) Short Interest Update

Biora Therapeutics, Inc. (NASDAQ:BIOR) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totalling 1,340,000 shares, a growth of 13.6% from the March 15th total of 1,180,000 shares. Based on an average daily volume of 464,400 shares, the days-to-cover ratio is currently 2.9 days. Currently, 4.2% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating on shares of Biora Therapeutics in a research report on Tuesday, January 2nd.

Hedge Funds Weigh In On Biora Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CIBC Asset Management Inc acquired a new position in Biora Therapeutics during the first quarter worth $42,000. Virtu Financial LLC acquired a new position in Biora Therapeutics during the fourth quarter worth $27,000. State Street Corp boosted its stake in Biora Therapeutics by 88.2% during the second quarter. State Street Corp now owns 33,073 shares of the company’s stock worth $127,000 after buying an additional 15,500 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in Biora Therapeutics during the first quarter worth $118,000. Finally, Bank of New York Mellon Corp acquired a new position in Biora Therapeutics during the third quarter worth $27,000. Institutional investors and hedge funds own 43.74% of the company’s stock.

Biora Therapeutics Trading Up 0.2 %

NASDAQ BIOR traded up $0.00 on Tuesday, reaching $0.62. 215,741 shares of the company were exchanged, compared to its average volume of 452,254. The business’s fifty day moving average price is $0.99 and its 200 day moving average price is $1.30. The stock has a market capitalization of $22.28 million, a P/E ratio of -0.07 and a beta of 1.09. Biora Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $6.70.

Biora Therapeutics Company Profile

Biora Therapeutics, Inc, a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases.